Lefort et al. used breast cancer patient-derived xenografts (PDXs) to test the efficacy of motixafortide compared to the first generation CXCR4 inhibitor, plerixafor, to decrease tumor growth and metastasis [218]. The gene discussed is CXCR4; the disease is neoplasm.